Vakar Prilenia rīkoja tīmekļa semināru, kurā tika sniegta jaunākā informācija par Pridopidīna III fāzes pētījumu. Paldies visiem, kas pievienojās, un īpašs paldies mūsu lektoriem Maiklam Heidenam, Endrjū Feiginam, Ralfam Reilmanam un Annai Roserei, kā arī Dinai de Sousai no Eiropas Huntingtona asociācijas. Sekojiet līdzi, lai redzētu vairāk pasākumu izpratnes mēneša maijā! 
Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South America. In this project, called Explore for Huntington, Dimitri visited several Lasīt vairāk...
December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net Lasīt vairāk...
The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan further development of dalzanemdor CAMBRIDGE, Lasīt vairāk...
Latvian 
English 
Arabic 
Bulgarian 
Chinese 
Czech 
Danish 
Dutch 
Estonian 
Finnish 
French 
German 
Greek 
Hungarian 
Indonesian 
Italian 
Japanese 
Lithuanian 
Polish 
Portuguese 
Romanian 
Russian 
Slovak 
Slovenian 
Spanish 
Swedish 
Turkish 
Ukrainian
0 Komentārs